Alexandra Goll
Director/Board Member at Cerenis Therapeutics, Inc.
Network origin in Alexandra Goll first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
TVM Capital GmbH
 TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management.
36
| Private Company | Investment Managers | 36 |
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ.
18
| Subsidiary | Pharmaceuticals: Other | 18 |
Cerenis Therapeutics, Inc.
 Cerenis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cerenis Therapeutics, Inc. discovers, develops and commercializes drugs for the treatment of cardiovascular and metabolic diseases. It focuses on discovery, development, and commercialization of HDL therapies. Cerenis Therapeutics is located in Ann Arbor, MI.
10
| Subsidiary | Pharmaceuticals: Major | 10 |
| Public Company | Pharmaceuticals: Major | 10 | |
Biovertis AG
 Biovertis AG Pharmaceuticals: MajorHealth Technology Biovertis AG operates as a clinical stage pharmaceutical company. It develops small molecule drugs against proprietary microbial antigens. The firm discovers and develops antimicrobial drugs for infections caused by antibiotic-resistant bacterial pathogens. The company was founded by Erich Felber, Uwe von Ahsen, and Alexander Ullrich von Gabain in 2003 and is headquartered in Vienna, Austria.
4
| Subsidiary | Pharmaceuticals: Major | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Alexandra Goll via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| ABIONYX PHARMA | Pharmaceuticals: Major | Director/Board Member Director/Board Member Founder Director/Board Member Chief Tech/Sci/R&D Officer Chief Executive Officer Director/Board Member Chief Executive Officer | |
| Ludwig-Maximilians-Universität München | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree Graduate Degree Undergraduate Degree Doctorate Degree Doctorate Degree | |
Arbutus Biopharma, Inc.
 Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Biotechnology | Director/Board Member Founder Director/Board Member Founder | |
| University of Wisconsin | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree Undergraduate Degree | |
| ARBUTUS BIOPHARMA CORPORATION | Pharmaceuticals: Major | Chief Operating Officer Director/Board Member Chief Tech/Sci/R&D Officer | |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Corporate Officer/Principal General Counsel Sales & Marketing | |
Definiens AG
 Definiens AG Packaged SoftwareTechnology Services Definiens AG is a holding company, which engages in the development and market of biomedical imaging and data analysis software solutions. The firm specializes in the design and manufacture of imaging software suites for drug discovery, development, and diagnostics applications. It engages in the custom image analysis projects for the biopharmaceutical industry, spanning drug discovery, translational research, and clinical research. It offers image analysis processing, integration and deployment, planning, and consulting services. The company was founded by Gerd Binnig in 1994 and is headquartered in Munich, Germany. | Packaged Software | Director/Board Member Corporate Officer/Principal Director/Board Member | |
| Yale University | College/University | Undergraduate Degree Graduate Degree Doctorate Degree | |
| VIVORYON THERAPEUTICS N.V. | Biotechnology | Director/Board Member Director/Board Member Chairman | |
| 2INVEST AG | Financial Conglomerates | Director/Board Member Director/Board Member Director/Board Member | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Doctorate Degree Graduate Degree | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
NOXXON Pharma AG
 NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Biotechnology | Director/Board Member Chairman Chairman | |
| BIOMARIN PHARMACEUTICAL INC. | Biotechnology | Director/Board Member Chief Executive Officer | |
| CHIASMA, INC. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| Harvard Medical School | College/University | Doctorate Degree Corporate Officer/Principal | |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
 F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Medical Specialties | Director/Board Member Director/Board Member | |
| The University of Chicago | College/University | Corporate Officer/Principal Masters Business Admin | |
RITTERSHAUS Rechtsanwälte Partnerschaftsgesellschaft mbB
 RITTERSHAUS Rechtsanwälte Partnerschaftsgesellschaft mbB Miscellaneous Commercial ServicesCommercial Services RITTERSHAUS Rechtsanwälte Partnerschaftsgesellschaft mbB is a law firm based in Mannheim, Germany. The German company has a unique perspective on the legal world and operates differently from traditional law firms. The private company's description emphasizes its distinctiveness and alternative approach to legal services. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| European Private Equity & Venture Capital Association | Chairman Director/Board Member | ||
| Stephen M. Ross School of Business | College/University | Masters Business Admin Masters Business Admin | |
OMRIX Biopharmaceuticals, Inc.
 OMRIX Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| ESPERION THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Operating Officer | |
Antios Therapeutics, Inc.
 Antios Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Antios Therapeutics, Inc. operates as a biopharmaceutical company devoted to developing therapies for viral diseases. The company was founded by Abel De La Rosa, Doug Mayers and Idean Marvasty on October 30, 2018 and is headquartered in Atlanta, GA. | Pharmaceuticals: Major | Director/Board Member Founder | |
| EVOTEC SE | Pharmaceuticals: Major | Director/Board Member Chairman | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Doctorate Degree Undergraduate Degree | |
Ambu Innovation GmbH
 Ambu Innovation GmbH Medical SpecialtiesHealth Technology Ambu Innovation GmbH engages in the development and distribution of single-use and light-weight robotically-assisted high definition endoscopy products in the field of gastroenterology and gastro-intestinal surgery. Its products include invendoscope SC210, invendo ScopeController, and invendo SPU E210. The company was founded in 1992 and is headquartered in Kissing, Germany. | Medical Specialties | Director/Board Member Director/Board Member | |
APEIRON Biologics AG
 APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | Biotechnology | Director/Board Member Chief Executive Officer | |
Apogenix AG
 Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Biotechnology | Chairman Director/Board Member | |
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal | |
| dievini Verwaltungs GmbH | Chief Executive Officer Chief Executive Officer | ||
| Seton Hall University | College/University | Masters Business Admin Undergraduate Degree | |
Molecular Health, Inc.
 Molecular Health, Inc. Packaged SoftwareTechnology Services Molecular Health, Inc. operates as a cloud-based healthcare decision support technology to enable evidence-based treatment decisions. The company was founded in 2004 and is headquartered in Boston, MA. | Packaged Software | Chairman Director/Board Member | |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| AC IMMUNE SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Febit, Inc. | Director/Board Member Chairman | ||
Molecular Health GmbH
 Molecular Health GmbH Miscellaneous Commercial ServicesCommercial Services Part of Posbelduf Biotech AG, Molecular Health GmbH is a German management consulting company. The company is based in Heidelberg, Germany. The company was founded in 2004 by Friedrich von Bohlen und Halbach. Friedrich von Bohlen und Halbach has been the CEO since 2004. | Miscellaneous Commercial Services | Chief Executive Officer Chairman | |
dievini Hopp BioTech holding GmbH & Co. KG
 dievini Hopp BioTech holding GmbH & Co. KG Investment ManagersFinance dievini Hopp BioTech holding GmbH & Co. KG operates as a private investment and consulting firm. It invests in companies related to the life and health sciences. It focuses with companies that diagnoses and provides therapy in the fields of oncology, neurology, infectious diseases, cell therapy and drug delivery systems. The company is headquartered in Walldorf, Germany. | Investment Managers | Private Equity Investor Founder | |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Biotechnology | Director/Board Member Director/Board Member | |
febit holding GmbH
 febit holding GmbH Medical/Nursing ServicesHealth Services febit holding GmbH engages in the design and development of technologies used for DNA analysis. It specializes in technologies with applications in genomic research, RNA expression profiling, and other diagnostic and molecular biology fields. The company was founded by Markus Beier, Ramon Gueimil, Peer F. Staehler, Matthias Scheffler, and Cord F. Stähler in 2005 and is headquartered in Heidelberg, Germany. | Medical/Nursing Services | Director/Board Member Chairman | |
| University of Freiburg | College/University | Doctorate Degree Graduate Degree |
Statistics
International
| United States | 23 |
| Germany | 20 |
| France | 4 |
| Austria | 4 |
| Netherlands | 2 |
Sectoral
| Health Technology | 26 |
| Consumer Services | 12 |
| Commercial Services | 6 |
| Technology Services | 3 |
| Finance | 3 |
Operational
| Director/Board Member | 426 |
| Corporate Officer/Principal | 136 |
| Chairman | 124 |
| Chief Executive Officer | 83 |
| Private Equity Investor | 57 |
Most connected contacts
| Insiders | |
|---|---|
| Ansbert Gadicke | 56 |
| G. Steven Burrill | 44 |
| Christof Hettich | 40 |
| Friedrich von Bohlen und Halbach | 36 |
| Johan Rutger Christenson | 35 |
| Stephen Hoffman | 33 |
| Helmut Schühsler | 28 |
| Hubert Birner | 27 |
| Michael Davidson | 27 |
| Mary L. Campbell | 27 |
| Denis Lucquin | 26 |
| David Ebsworth | 26 |
| Marios Fotiadis | 25 |
| Robert Williamson | 25 |
| Thomas D. Szucs | 23 |
- Stock Market
- Insiders
- Alexandra Goll
- Company connections
